Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-U02 substudy 02B in unresectable stage III/IV melanoma
MOH_2020-03-16_008775Phase 2Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Jan 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of pembrolizumab and vibostolimab in melanoma (2 arms), sponsored by Merck & Co. Primary endpoints: Safety and tolerability and Objective response rate. Started Jan 2020; status: active, not recruiting.
02
Drugs
pembrolizumabvibostolimab
03
Conditions
melanoma
Beyond the preview
Go deeper on MOH_2020-03-16_008775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-03-16_008775.